Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double blind, placebo-controlled trial.

Trial Profile

Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: A randomized, double blind, placebo-controlled trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Mar 2016

At a glance

  • Drugs Flunisolide (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 07 Mar 2016 Results of post hoc analyses from this and other trial, presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 30 Aug 2013 The US FDA has approved the addition of data from this study in the prescribing information for flunisolide, according to a Meda media release.
    • 11 Oct 2011 Results published in the Annals of Allergy, Asthma & Immunology, according to an Acton Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top